CN105997850A - 一种用于治疗痤疮的外用膏剂及其制备方法 - Google Patents

一种用于治疗痤疮的外用膏剂及其制备方法 Download PDF

Info

Publication number
CN105997850A
CN105997850A CN201610618689.3A CN201610618689A CN105997850A CN 105997850 A CN105997850 A CN 105997850A CN 201610618689 A CN201610618689 A CN 201610618689A CN 105997850 A CN105997850 A CN 105997850A
Authority
CN
China
Prior art keywords
volume ratio
water
described water
solution
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610618689.3A
Other languages
English (en)
Inventor
朱玉水
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610618689.3A priority Critical patent/CN105997850A/zh
Publication of CN105997850A publication Critical patent/CN105997850A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种用于治疗痤疮(青春痘)的外用膏剂,其包含氯霉素、新霉素、曲安奈德,所述外用膏剂还包含丙二醇、乙醇、PEG400、平平加0‑20、棕榈酸异丙酯、十八醇、单硬脂酸甘油酯、医用白凡士林、羟苯乙酯、水。本发明还涉及所述外用膏剂的制备方法,其包括以下步骤:1)将丙二醇、PEG400、十八醇和平平加0‑20加入水中配制成水溶液;2)将棕榈酸异丙酯、单硬脂酸甘油酯和羟苯乙酯加入乙醇中配置成乙醇溶液;3)将所述水溶液与所述乙醇溶液合并成混合溶液;4)向所述混合溶液中加入医用凡士林;5)依次加入氯霉素、新霉素、曲安奈德,搅拌至膏状,即得到所述外用膏剂。本发明的外用膏剂可有效治疗痤疮(青春痘),具有消炎止痒、润肤消痤、除痘去斑等功效,并且无不良反应。

Description

一种用于治疗痤疮的外用膏剂及其制备方法
技术领域
本发明涉及医药领域,更特别的,涉及一种用于治疗痤疮的外用膏剂。
背景技术
痤疮,又称青春痘,是毛囊皮脂腺单位的一种慢性炎症性皮肤病。主要好发于青少年,对青少年的心理和社交影响很大,但青春期后往往能自然减轻或痊愈。临床表现以好发于面部的粉刺、丘疹、脓疱、结节等多形性皮损为特点。痤疮的发生主要与皮脂分泌过多、毛囊皮脂腺导管堵塞、细菌感染和炎症反应等因素密切相关。进入青春期后人体内雄激素特别是睾酮的水平迅速升高,促进皮脂腺发育并产生大量皮脂。毛囊中多种微生物尤其是痤疮丙酸杆菌大量繁殖,痤疮丙酸杆菌产生的脂酶分解皮脂生成游离脂肪酸,最终诱导并加重炎症反应。痤疮的非炎症性皮损表现为开放性和闭合性粉刺。
典型的痤疮治疗包括含过氧化苯甲酰、类维生素A或抗生素和过氧化苯甲酰的组合的疗法。然而,这些疗法对皮肤有刺激性并可导致过度干燥、发红、过敏和脱皮。这些疗法可能需要3-6周时间来将炎性痤疮病变减少50%。典型的痤疮治疗产品起效所需的时间量和它们展示出的耐受性问题导致使用者在按规定使用这些产品时表现出不依从;极少体验到痤疮减少;且不太可能再次购买痤疮产品。
因此,需要更有效且易于使用,同时使对皮肤的刺激性副作用最小化的痤疮治疗疗法。因此,需要改进的痤疮治疗产品。
发明内容
为了解决以上技术问题,本发明提供了一种用于治疗痤疮的外用膏剂,其特征在于,包含氯霉素、新霉素、曲安奈德。
进一步的,所述外用膏剂还包含丙二醇、乙醇、PEG400、平平加0-20、棕榈酸异丙酯、十八醇、单硬脂酸甘油酯、医用白凡士林、羟苯乙酯、水。
本发明还提供了以上外用膏剂的制备方法,包括以下步骤:
1)将丙二醇、PEG400、十八醇和平平加0-20加入水中配制成水溶液;
2)将棕榈酸异丙酯、单硬脂酸甘油酯和羟苯乙酯加入乙醇中配置成乙醇溶液;
3)将所述水溶液与所述乙醇溶液合并成混合溶液;
4)向所述混合溶液中加入医用凡士林;
5)依次加入氯霉素、新霉素、曲安奈德,搅拌至膏状,即得到所述外用膏剂。
优选地,在所述水溶液中,所述丙二醇与所述水的体积比为0.3-3:10,所述PEG400与所述水的质量体积比为0.1-0.3g/mL,所述十八醇与所述水的质量体积比为0.01-0.1g/mL,所述平平加0-20与所述水的质量体积比为0.01-0.04g/mL。
优选地,在所述乙醇溶液中,所述乙醇与所述水的体积比为0.5-2:1,所述棕榈酸异丙酯与所述水的质量体积比为0.02-0.1g/mL,所述单硬脂酸甘油酯与所述水的质量体积为0.002-0.005g/mL,所述羟苯乙酯与所述水的质量体积比为0.003-0.005g/mL。
优选地,步骤4)中加入的所述医用凡士林与所述水的质量体积比为1g/mL,并且所述医用凡士林的温度为45℃。
优选地,所述氯霉素与所述水的质量体积比为0.3-1g/mL、所述新霉素与所述水的效价体积比为30-300单位/mL、所述曲安奈德与所述水的质量体积比为0.01-1mg/mL。
优选地,所述方法包括以下步骤:
1)向水中依次缓慢加入与所述水的体积比为0.3-3:10的丙二醇、与所述水的质量体积比为0.1-0.3g/mL的PEG400、与所述水的质量体积比为0.01-0.1g/mL的十八醇、与所述水的质量体积比为0.01-0.04g/mL的平平加,边加边搅拌至形成均匀的水溶液;
2)向与所述水的体积比为0.5-2:1的乙醇中依次缓慢加入与所述水的质量体积比为0.02-0.1g/mL的棕榈酸异丙酯、与所述水的质量体积为0.002-0.005g/mL的单硬脂酸甘油酯、与所述水的质量体积比为0.003-0.005g/mL的羟苯乙酯,边加边搅拌至形成均匀的乙醇溶液;
3)将所述水溶液与所述乙醇溶液合并,搅拌均匀,形成混合溶液,
4)向所述混合溶液中缓慢加入45℃的与所述水的质量体积比为1g/mL的医用凡士林;
5)依次加入与所述水的质量体积比为0.3-1g/mL的氯霉素、与所述水的效价体积比为30-300单位/mL新霉素、与所述水的质量体积比为0.01-1mg/mL曲安奈德,搅拌至膏状,即得到所述外用膏剂。
本发明的外用膏剂可有效治疗痤疮,具有消炎止痒、润肤消痤、除痘去斑等功效,并且无不良反应。
具体实施方式
以下结合实例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
使用以下方法制备用于治疗痤疮的外用膏剂:
1)向水中依次缓慢加入丙二醇、PEG400、十八醇、平平加,边加边搅拌至形成均匀的水溶液;
2)向乙醇中依次缓慢加入棕榈酸异丙酯、单硬脂酸甘油酯、羟苯乙酯,边加边搅拌至形成均匀的乙醇溶液;
3)将所述水溶液与所述乙醇溶液合并,搅拌均匀,形成混合溶液,
4)向所述混合溶液中缓慢加入45℃的医用凡士林;
5)依次加入氯霉素、新霉素、曲安奈德,搅拌至晶莹透明柔白细腻的膏状,即得到所述外用膏剂。经高压消毒灭菌后,可将外用膏剂可分装于小瓶中,每瓶为20g、40g或80g。
除非特殊说明,否则以上步骤都在常温下进行。各步骤中所加的各组分的量如表1所示。
表1制备过程中所加各组分的量
实施例1 实施例2 实施例3
氯霉素(g) 30 60 100
新霉素(单位) 3000 15000 30000
曲安奈德(mg) 1 50 100
丙二醇(mL) 3 15 30
乙醇(mL) 50 150 200
PEG400(g) 10 20 30
平平加0-20(g) 1 2 4
棕榈酸异丙酯(g) 2 6 10
十八醇(g) 1 5 10
单硬脂酸甘油酯(g) 0.2 0.3 0.5
医用白凡士林(g) 100 100 100
羟苯乙酯(g) 0.3 0.4 0.5
水(mL) 100 100 100
使用时,用清水或香皂洗净面部,将少许外用膏剂涂抹于面部的痤疮处。用药期间,禁用油脂类、粉脂类化妆品,禁食辛辣油腻上火类食物,忌饮酒。
使用本发明的外用膏剂门诊治疗数万例痤疮患者,治愈率达98%,有效率达100%,无不良反应。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。

Claims (8)

1.一种用于治疗痤疮的外用膏剂,其特征在于,包含氯霉素、新霉素、曲安奈德。
2.根据权利要求1所述的外用膏剂,其特征在于,还包含丙二醇、乙醇、PEG400、平平加0-20、棕榈酸异丙酯、十八醇、单硬脂酸甘油酯、医用白凡士林、羟苯乙酯、水。
3.一种如权利要求1或2所述的外用膏剂的制备方法,其特征在于,包括以下步骤:
1)将丙二醇、PEG400、十八醇和平平加0-20加入水中配制成水溶液;
2)将棕榈酸异丙酯、单硬脂酸甘油酯和羟苯乙酯加入乙醇中配置成乙醇溶液;
3)将所述水溶液与所述乙醇溶液合并成混合溶液;
4)向所述混合溶液中加入医用凡士林;
5)依次加入氯霉素、新霉素、曲安奈德,搅拌至膏状,即得到所述外用膏剂。
4.根据权利要求3所述的制备方法,其特征在于,在所述水溶液中,所述丙二醇与所述水的体积比为0.3-3:10,所述PEG400与所述水的质量体积比为0.1-0.3g/mL,所述十八醇与所述水的质量体积比为0.01-0.1g/mL,所述平平加0-20与所述水的质量体积比为0.01-0.04g/mL。
5.根据权利要求3所述的制备方法,其特征在于,在所述乙醇溶液中,所述乙醇与所述水的体积比为0.5-2:1,所述棕榈酸异丙酯与所述水的质量体积比为0.02-0.1g/mL,所述单硬脂酸甘油酯与所述水的质量体积为0.002-0.005g/mL,所述羟苯乙酯与所述水的质量体积比为0.003-0.005g/mL。
6.根据权利要求3所述的制备方法,其特征在于,步骤4)中加入的所述医用凡士林与所述水的质量体积比为1g/mL,并且所述医用凡士林的温度为45℃。
7.根据权利要求3所述的制备方法,其特征在于,所述氯霉素与所述水的质量体积比为0.3-1g/mL、所述新霉素与所述水的效价体积比为30-300单位/mL、所述曲安奈德与所述水的质量体积比为0.01-1mg/mL。
8.根据权利要求3所述的制备方法,其特征在于,包括以下步骤:
1)向水中依次缓慢加入与所述水的体积比为0.3-3:10的丙二醇、与所述水的质量体积比为0.1-0.3g/mL的PEG400、与所述水的质量体积比为0.01-0.1g/mL的十八醇、与所述水的质量体积比为0.01-0.04g/mL的平平加,边加边搅拌至形成均匀的水溶液;
2)向与所述水的体积比为0.5-2:1的乙醇中依次缓慢加入与所述水的质量体积比为0.02-0.1g/mL的棕榈酸异丙酯、与所述水的质量体积为0.002-0.005g/mL的单硬脂酸甘油酯、与所述水的质量体积比为0.003-0.005g/mL的羟苯乙酯,边加边搅拌至形成均匀的乙醇溶液;
3)将所述水溶液与所述乙醇溶液合并,搅拌均匀,形成混合溶液;
4)向所述混合溶液中缓慢加入45℃的与所述水的质量体积比为1g/mL的医用凡士林;
5)依次加入与所述水的质量体积比为0.3-1g/mL的氯霉素、与所述水的效价体积比为30-300单位/mL新霉素、与所述水的质量体积比为0.01-1mg/mL曲安奈德,搅拌至膏状,即得到所述外用膏剂。
CN201610618689.3A 2016-08-01 2016-08-01 一种用于治疗痤疮的外用膏剂及其制备方法 Pending CN105997850A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610618689.3A CN105997850A (zh) 2016-08-01 2016-08-01 一种用于治疗痤疮的外用膏剂及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610618689.3A CN105997850A (zh) 2016-08-01 2016-08-01 一种用于治疗痤疮的外用膏剂及其制备方法

Publications (1)

Publication Number Publication Date
CN105997850A true CN105997850A (zh) 2016-10-12

Family

ID=57133583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610618689.3A Pending CN105997850A (zh) 2016-08-01 2016-08-01 一种用于治疗痤疮的外用膏剂及其制备方法

Country Status (1)

Country Link
CN (1) CN105997850A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106726689A (zh) * 2016-12-24 2017-05-31 叶宗瑞 一种防治痤疮的面霜及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528327A (zh) * 2003-09-29 2004-09-15 中国医学科学院皮肤病研究所 专治痤疮的复方外用药物及其制备方法
CN103933051A (zh) * 2014-05-12 2014-07-23 广东台城制药股份有限公司 一种曲咪新乳膏及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1528327A (zh) * 2003-09-29 2004-09-15 中国医学科学院皮肤病研究所 专治痤疮的复方外用药物及其制备方法
CN103933051A (zh) * 2014-05-12 2014-07-23 广东台城制药股份有限公司 一种曲咪新乳膏及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李爱英等: ""复方曲氯乳膏的制备及临床应用"", 《中国医院药学杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106726689A (zh) * 2016-12-24 2017-05-31 叶宗瑞 一种防治痤疮的面霜及其制备方法

Similar Documents

Publication Publication Date Title
US20210077509A1 (en) Compositions for the improved treatment of acne and related disorders
RU2491917C2 (ru) Наноэмульсия
JP5432470B2 (ja) セラミド溶液及び皮膚外用剤
JP6132108B2 (ja) ヒドロゲル形成材料、プレミックス及びヒドロゲル形成方法
US20170014517A1 (en) Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders
CN111329885B (zh) 改善或预防高原红症状的药物组合物、化妆品组合物及其制备方法和化妆品
CN112292116A (zh) 抗痤疮的化妆用制剂
ES2766377T3 (es) Composición para la profilaxis de la candidiasis
EP2925290A1 (en) Waxes having oil-in-water self-emulsifying and water gel-forming properties, compositions, uses and methods relating to same
JP2000191525A (ja) 皮膚外用剤組成物
JP6684325B2 (ja) 使用時泡状を呈する外用医薬の製造方法
JP6545933B2 (ja) 外用組成物
CN105997850A (zh) 一种用于治疗痤疮的外用膏剂及其制备方法
US6177413B1 (en) Stabilized aspirin compositions and method of preparation for oral and topical use
RU2529809C1 (ru) Детский крем для ежедневного ухода с пантенолом
JP2021113221A (ja) ロキソプロフェン含有の医薬製剤(に)
JP2010030910A (ja) 皮膚外用剤
JP2019048890A (ja) 泡状外用医薬組成物
JP5233149B2 (ja) アダパレン含有外用剤組成物
JP2015203029A (ja) 乾皮症又はアトピー皮膚炎用の医薬組成物及び医薬
EP3643288A1 (en) Liquids having oil-in-water self-emulsifying properties, compositions, uses and methods relating to same
CN106560178A (zh) 一种含厚朴酚及和厚朴酚与非甾体抗炎药组合物及其应用
JP2009256255A (ja) クレンジング機能を有する皮膚外用剤
US20190021992A1 (en) New improved composition comprising at least one cadotril
JP6180822B2 (ja) 医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161012

RJ01 Rejection of invention patent application after publication